Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

Iyer SN, Drake AJ 3rd, West RL, Mendez CE, Tanenberg RJ

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Jan 2012Cited by 35 (Europe PMC)

PMID22068258DOI10.4158/ep11264.crPepBankPUB-22068258

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A woman receiving exenatide plus sitagliptin presented with severe abdominal pain, vomiting and fever requiring hospital admission.
In plain wordsA woman receiving exenatide plus sitagliptin had severe abdominal pain, vomiting and fever and needed hospital admission.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePresenting symptoms: severe abdominal pain, vomiting and fever, requiring hospital admission
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
A 76-year-old woman with a history of type 2 diabetes mellitus presented with severe abdominal pain, vomiting, and fever requiring hospital admission.
2 context sentences(design, population, supporting numbers)
Summary · context
She had been treated with exenatide for 3 years to manage her diabetes mellitus.
Summary · context
A few weeks before presentation, sitagliptin was added, presumably to further optimize her glycemic control.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2206825801
02HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A woman receiving exenatide plus sitagliptin developed acute pancreatitis, confirmed at autopsy as necrotizing pancreatitis with complete pancreatic digestion.
In plain wordsA woman receiving exenatide plus sitagliptin developed pancreatitis, with complete destruction of the pancreas confirmed at autopsy.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableAcute necrotizing pancreatitis
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Autopsy findings demonstrated acute necrotizing pancreatitis with complete digestion of the pancreas.
4 context sentences(design, population, supporting numbers)
Summary · context
Acute pancreatitis was diagnosed during hospital admission.
Summary · context
A 76-year-old woman with a history of type 2 diabetes mellitus presented with severe abdominal pain, vomiting, and fever requiring hospital admission.
Summary · context
She had been treated with exenatide for 3 years to manage her diabetes mellitus.
Summary · context
A few weeks before presentation, sitagliptin was added, presumably to further optimize her glycemic control.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2206825804
03HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesOther
A woman receiving exenatide plus sitagliptin had serum amylase of 1136 U/L at presentation with pancreatitis.
In plain wordsA woman receiving exenatide plus sitagliptin had elevated amylase of 1136 U/L when she presented with pancreatitis.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum amylase
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Measurements
Serum amylase
1136 U/L
initial presentation
Source sentences
Summary
At initial presentation, her serum amylase concentration was 1136 U/L (reference range, 10-130 U/L) and her lipase concentration was greater than 3500 U/L (reference range, 0-75 U/L).
3 context sentences(design, population, supporting numbers)
Summary · context
A 76-year-old woman with a history of type 2 diabetes mellitus presented with severe abdominal pain, vomiting, and fever requiring hospital admission.
Summary · context
She had been treated with exenatide for 3 years to manage her diabetes mellitus.
Summary · context
A few weeks before presentation, sitagliptin was added, presumably to further optimize her glycemic control.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2206825805
04HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesOther
A woman receiving exenatide plus sitagliptin had lipase greater than 3500 U/L at presentation with pancreatitis.
In plain wordsA woman receiving exenatide plus sitagliptin had elevated lipase greater than 3500 U/L when she presented with pancreatitis.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum lipase
Study
n = 1
Outcome group
Adverse events · Gastrointestinal
Measurements
Lipase
> 3500 U/L
initial presentation
Source sentences
Summary
At initial presentation, her serum amylase concentration was 1136 U/L (reference range, 10-130 U/L) and her lipase concentration was greater than 3500 U/L (reference range, 0-75 U/L).
3 context sentences(design, population, supporting numbers)
Summary · context
A 76-year-old woman with a history of type 2 diabetes mellitus presented with severe abdominal pain, vomiting, and fever requiring hospital admission.
Summary · context
She had been treated with exenatide for 3 years to manage her diabetes mellitus.
Summary · context
A few weeks before presentation, sitagliptin was added, presumably to further optimize her glycemic control.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2206825806
05HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A woman with pancreatitis during exenatide plus sitagliptin treatment deteriorated despite aggressive care and died.
In plain wordsA woman with pancreatitis during exenatide plus sitagliptin treatment died despite aggressive care.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDeath
Study
n = 1
Outcome group
Mortality · Whole body
Source sentences
Summary
After initial brief improvement, her symptoms worsened, and despite aggressive care, her clinical state deteriorated and she died.
4 context sentences(design, population, supporting numbers)
Summary · context
Acute pancreatitis was diagnosed during hospital admission.
Summary · context
A 76-year-old woman with a history of type 2 diabetes mellitus presented with severe abdominal pain, vomiting, and fever requiring hospital admission.
Summary · context
She had been treated with exenatide for 3 years to manage her diabetes mellitus.
Summary · context
A few weeks before presentation, sitagliptin was added, presumably to further optimize her glycemic control.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2206825807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.